Comprehensive understanding of the precautions for the use of corvalizumab

Crovalimab,is an innovative complementC5 inhibitor designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in patients 13 years and older and weighing at least 40kg. Before using this drug, patients need to fully understand its indications and precautions for use to ensure safe and effective treatment.

Patients must pay special attention to their meningococcal vaccination status before using kovalizumab. Be sure to complete or update meningococcal vaccination at least2weeks before the first dose of kovalizumab. If vaccination has not been completed, it should be started as soon as possible and combined with antibiotics if necessary to follow the doctor's recommendations medication. Even if you have been vaccinated in the past, your doctor may decide whether additional vaccinations are needed based on your circumstances. It should be emphasized that the meningococcal vaccine does not prevent all types of meningococcal infections, and you should seek medical attention immediately if you develop severe symptoms.

Before starting treatment with corvalizumab, patients should also tell their doctor in detail about all of their medical conditions, including whether they have infections or fevers, whether they are pregnant or trying to become pregnant, whether they are breastfeeding, and all medications they are taking, whether prescription, over-the-counter, vitamins, or herbal supplements. In particular, it is important to inform your doctor if the patient is currently or has been treated with other complementC5inhibitors to avoid potential drug interactions or risks.

2024On February 2 6, China’s State Food and Drug Administration approved the launch of kovalizumab injection, with the trade name Persense. This is also the first time it has been approved in any country in the world. 2024 Year 6 Month Approved for marketing in the United States under the trade name Piasky.

Since it has not been on the market for a long time, it has not yet been included in my country's medical insurance system. The price has not yet been determined, and the drug price may be affected by different factors such as sales channels, regions, and medical insurance policies, and the actual price may fluctuate.

Kovalizumab, as a monoclonal antibody, works by attaching to the C5 complement protein, thereby preventing the complement system from being overactive and protecting the patient's own cells from damage, especially red blood cells, helping to relieve the symptoms of PNH. During use, patients should follow the doctor's instructions, pay close attention to any adverse reactions, and communicate with the doctor in a timely manner to ensure the safety and effectiveness of the treatment.

Reference link:https://www.accessdata.fda.gov/drugsatfda docs/label/2024/761388s000lbl.pdf